Lova L. Sun

Oncology

3400 Civic Center Boulevard
West Pavilion, 2nd Floor
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 180 publications

EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non-Small Cell Lung Cancer.

EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non-Small Cell Lung Cancer.

Journal: JCO precision oncology

Published: July 15, 2026

Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461].

Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461].

Journal: The journal of liquid biopsy

Published: June 29, 2026

Poor Performance Status Associated With Inferior Tarlatamab Outcomes in a Large, Multi-institution Real-World Database of Patients With 2L + ES-SCLC.

Poor Performance Status Associated With Inferior Tarlatamab Outcomes in a Large, Multi-institution Real-World Database of Patients With 2L + ES-SCLC.

Journal: Clinical lung cancer

Published: May 19, 2026

Systemic Treatment of Thyroid Cancer: ASCO Guideline.

Systemic Treatment of Thyroid Cancer: ASCO Guideline.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 01, 2026

The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing.

The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing.

Journal: The journal of liquid biopsy

Published: February 08, 2026

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 17, 2025

Long-Term Results of a Phase 2 Clinical Trial of Radiation Volume and Dose Deintensification Following Transoral Robotic Surgery and Neck Dissection for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.

Long-Term Results of a Phase 2 Clinical Trial of Radiation Volume and Dose Deintensification Following Transoral Robotic Surgery and Neck Dissection for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.

Journal: International journal of radiation oncology, biology, physics

Published: November 15, 2025

Recurrent/metastatic relapse after definitive treatment for HNSCC: timing, patterns, and survival.

Recurrent/metastatic relapse after definitive treatment for HNSCC: timing, patterns, and survival.

Journal: Frontiers in oncology

Published: November 03, 2025

Molecular Profiling and Real-world Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.

Molecular Profiling and Real-world Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 17, 2025

BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.

BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.

Journal: Molecular cancer therapeutics

Published: September 05, 2025

Cardiac substructure radiotherapy dose and changes in physical activity and quality of life after chemoradiotherapy for NSCLC: a secondary analysis of the CLARITY prospective study.

Cardiac substructure radiotherapy dose and changes in physical activity and quality of life after chemoradiotherapy for NSCLC: a secondary analysis of the CLARITY prospective study.

Journal: Clinical and translational radiation oncology

Published: September 02, 2025

To Stop or Not to Stop: Is It Time to Reevaluate Immunotherapy Duration in Advanced/Metastatic NSCLC?

To Stop or Not to Stop: Is It Time to Reevaluate Immunotherapy Duration in Advanced/Metastatic NSCLC?

Journal: Clinical lung cancer

Published: August 27, 2025

Showing 1-12 of 180

Last Updated: 09/26/2026